S&P 500   4,348.70 (+0.43%)
DOW   34,107.16 (+0.11%)
QQQ   361.04 (+0.89%)
AAPL   176.04 (+1.21%)
MSFT   319.64 (+0.03%)
META   304.89 (+3.10%)
GOOGL   131.85 (+1.08%)
AMZN   131.49 (+1.67%)
TSLA   255.03 (-0.26%)
NVDA   418.76 (+2.09%)
NIO   8.64 (+2.25%)
BABA   88.65 (+5.40%)
AMD   97.97 (+1.94%)
T   15.14 (-1.11%)
F   12.63 (+3.52%)
MU   69.39 (+2.19%)
CGC   0.85 (+11.08%)
GE   112.97 (-0.02%)
DIS   82.35 (-0.46%)
AMC   7.88 (+2.34%)
PFE   32.52 (-1.00%)
PYPL   59.00 (+0.65%)
NFLX   384.22 (+0.02%)
S&P 500   4,348.70 (+0.43%)
DOW   34,107.16 (+0.11%)
QQQ   361.04 (+0.89%)
AAPL   176.04 (+1.21%)
MSFT   319.64 (+0.03%)
META   304.89 (+3.10%)
GOOGL   131.85 (+1.08%)
AMZN   131.49 (+1.67%)
TSLA   255.03 (-0.26%)
NVDA   418.76 (+2.09%)
NIO   8.64 (+2.25%)
BABA   88.65 (+5.40%)
AMD   97.97 (+1.94%)
T   15.14 (-1.11%)
F   12.63 (+3.52%)
MU   69.39 (+2.19%)
CGC   0.85 (+11.08%)
GE   112.97 (-0.02%)
DIS   82.35 (-0.46%)
AMC   7.88 (+2.34%)
PFE   32.52 (-1.00%)
PYPL   59.00 (+0.65%)
NFLX   384.22 (+0.02%)
S&P 500   4,348.70 (+0.43%)
DOW   34,107.16 (+0.11%)
QQQ   361.04 (+0.89%)
AAPL   176.04 (+1.21%)
MSFT   319.64 (+0.03%)
META   304.89 (+3.10%)
GOOGL   131.85 (+1.08%)
AMZN   131.49 (+1.67%)
TSLA   255.03 (-0.26%)
NVDA   418.76 (+2.09%)
NIO   8.64 (+2.25%)
BABA   88.65 (+5.40%)
AMD   97.97 (+1.94%)
T   15.14 (-1.11%)
F   12.63 (+3.52%)
MU   69.39 (+2.19%)
CGC   0.85 (+11.08%)
GE   112.97 (-0.02%)
DIS   82.35 (-0.46%)
AMC   7.88 (+2.34%)
PFE   32.52 (-1.00%)
PYPL   59.00 (+0.65%)
NFLX   384.22 (+0.02%)
S&P 500   4,348.70 (+0.43%)
DOW   34,107.16 (+0.11%)
QQQ   361.04 (+0.89%)
AAPL   176.04 (+1.21%)
MSFT   319.64 (+0.03%)
META   304.89 (+3.10%)
GOOGL   131.85 (+1.08%)
AMZN   131.49 (+1.67%)
TSLA   255.03 (-0.26%)
NVDA   418.76 (+2.09%)
NIO   8.64 (+2.25%)
BABA   88.65 (+5.40%)
AMD   97.97 (+1.94%)
T   15.14 (-1.11%)
F   12.63 (+3.52%)
MU   69.39 (+2.19%)
CGC   0.85 (+11.08%)
GE   112.97 (-0.02%)
DIS   82.35 (-0.46%)
AMC   7.88 (+2.34%)
PFE   32.52 (-1.00%)
PYPL   59.00 (+0.65%)
NFLX   384.22 (+0.02%)
NASDAQ:MRNA

Moderna (MRNA) Stock Forecast, Price & News

$99.41
-0.82 (-0.82%)
(As of 10:40 AM ET)
Compare
Today's Range
$98.51
$100.98
50-Day Range
$96.41
$126.43
52-Week Range
$95.02
$217.25
Volume
708,164 shs
Average Volume
3.61 million shs
Market Capitalization
$37.83 billion
P/E Ratio
36.68
Dividend Yield
N/A
Price Target
$155.52

Moderna MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
55.2% Upside
$155.52 Price Target
Short Interest
Bearish
5.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.71
Upright™ Environmental Score
News Sentiment
0.04mentions of Moderna in the last 14 days
Based on 42 Articles This Week
Insider Trading
Selling Shares
$27.17 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.32) to ($5.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

125th out of 965 stocks

Biological Products, Except Diagnostic Industry

13th out of 162 stocks


MRNA stock logo

About Moderna (NASDAQ:MRNA) Stock

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. 

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. 

MRNA Price History

MRNA Stock News Headlines

Moderna: Fortune Favors The Brave
Does This Message From Moderna Mean Bad News for Novavax?
"This Could be the Biggest Stock Story of 2023"
A.I. is set to create $7 trillion in new wealth but most investors are buying the wrong stocks. Learn what Wall Street insiders are buying here.
Moderna to Wind Down COVID Vaccine Production
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed
This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.
Moderna's Chart Messages Are Frustrating the Bulls
Moderna (NASDAQ:MRNA) Stock Price Down 5.7% on Insider Selling
Why Moderna Stock Is Sinking Today
Moderna’s Stock Is S&P 500’s Biggest Loser Today
Moderna Unusual Options Activity For September 15
Moderna Faces Tougher Competition in Its Next Chapter
Moderna (NASDAQ:MRNA) Price Target Cut to $140.00
See More Headlines
Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

MRNA Company Calendar

Last Earnings
8/03/2023
Today
9/21/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRNA
Fax
N/A
Employees
3,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$155.52
High Stock Price Forecast
$296.00
Low Stock Price Forecast
$93.00
Forecasted Upside/Downside
+55.2%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
18 Analysts

Profitability

Net Income
$8.36 billion
Pretax Margin
7.68%

Debt

Sales & Book Value

Annual Sales
$19.26 billion
Cash Flow
$21.37 per share
Book Value
$49.78 per share

Miscellaneous

Free Float
320,840,000
Market Cap
$38.15 billion
Optionable
Optionable
Beta
1.63

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Stephane BancelMr. Stephane Bancel (Age 50)
    CEO & Director
    Comp: $4.97M
  • Dr. Stephen Hoge M.D. (Age 47)
    Pres
    Comp: $2.41M
  • Mr. James M. Mock (Age 46)
    Chief Financial Officer
    Comp: $1.49M
  • Ms. Arpa Garay (Age 44)
    Chief Commercial Officer
    Comp: $2.67M
  • Dr. Jerh Collins Ph.D. (Age 57)
    Chief Technical Operations & Quality Officer
  • Dr. Melissa J. Moore Ph.D.
    Chief Scientific Officer & Member of Scientific Advisory Board
  • Mr. Brad Miller (Age 50)
    Chief Information Officer
  • Ms. Lavina Talukdar CFA
    Sr. VP & Head of Investor Relations
  • Ms. Shannon Thyme KlingerMs. Shannon Thyme Klinger (Age 52)
    Chief Legal Officer & Corp. Sec.
  • Colleen Hussey
    Sr. Director of Corp. Communications













MRNA Stock - Frequently Asked Questions

Should I buy or sell Moderna stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 3 sell ratings, 9 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings
or view top-rated stocks.

What is Moderna's stock price forecast for 2023?

18 Wall Street analysts have issued 12 month price objectives for Moderna's shares. Their MRNA share price forecasts range from $93.00 to $296.00. On average, they anticipate the company's stock price to reach $155.52 in the next twelve months. This suggests a possible upside of 55.2% from the stock's current price.
View analysts price targets for MRNA
or view top-rated stocks among Wall Street analysts.

How have MRNA shares performed in 2023?

Moderna's stock was trading at $179.62 at the beginning of the year. Since then, MRNA shares have decreased by 44.2% and is now trading at $100.23.
View the best growth stocks for 2023 here
.

When is Moderna's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MRNA earnings forecast
.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($3.62) EPS for the quarter, beating analysts' consensus estimates of ($3.84) by $0.22. The firm had revenue of $344 million for the quarter, compared to analysts' expectations of $307.67 million. Moderna had a trailing twelve-month return on equity of 6.62% and a net margin of 11.33%. The firm's revenue was down 92.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.24 EPS.

What is Stéphane Bancel's approval rating as Moderna's CEO?

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

When did Moderna IPO?

(MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

What is Moderna's stock symbol?

Moderna trades on the NASDAQ under the ticker symbol "MRNA."

Who are Moderna's major shareholders?

Moderna's stock is owned by many different institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (37.35%), Baillie Gifford & Co. (11.99%), BlackRock Inc. (6.35%), State Street Corp (3.74%), Geode Capital Management LLC (1.66%) and Capital World Investors (1.04%). Insiders that own company stock include David W Meline, Dustin A Moskovitz, Juan Andres, Lori M Henderson, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and W Don Cornwell.
View institutional ownership trends
.

How do I buy shares of Moderna?

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Moderna's stock price today?

One share of MRNA stock can currently be purchased for approximately $100.23.

How much money does Moderna make?

Moderna (NASDAQ:MRNA) has a market capitalization of $38.15 billion and generates $19.26 billion in revenue each year. The company earns $8.36 billion in net income (profit) each year or $2.71 on an earnings per share basis.

How many employees does Moderna have?

The company employs 3,900 workers across the globe.

How can I contact Moderna?

Moderna's mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.modernatx.com. The company can be reached via phone at (617) 714-6500 or via email at ir@modernatx.com.

This page (NASDAQ:MRNA) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -